Help manage the impact of vaginal atrophy on your patients’ lives

About 50% of postmenopausal women get pain or discomfort from vaginal atrophy, which can impact their quality of life significantly.1,2

Vaginal atrophy can cause many different symptoms, notably, burning, itching, pain during sex or passing urine, and vaginal dryness.3

Prescribing and Adverse event reporting information for BlisselⓇ can be found here.

NEW VIDEOS
CLICK TO PLAY

“How do women present with GSM symptoms”

Prescribing and adverse event reporting information can be found at the end of this video.

How do women present with GSM symptoms?


Women may struggle to talk about their symptoms, and might prefer their doctor to initiate the discussion.4

“Are there any symptoms that patients may hesitate to discuss?”

Prescribing and adverse event reporting information can be found at the end of this video.


Despite clear guidelines for treatment, half of women with postmenopausal genitourinary symptoms have never been prescribed any medication for their symptoms.5

“Current guidelines for GSM/VVA management.”

Prescribing and adverse event reporting information can be found at the end of this video.

NICE guidance states that the lowest possible dose vaginal oestrogen should be offered to women to manage the bothersome symptoms of vaginal atrophy.6

Prescribing and Adverse event reporting information for BlisselⓇ can be found here.

Order your FREE demonstration pack:

Please click here to order your FREE Blissel®(estriol 50micrograms/g) VAGINAL GEL
placebo demonstration pack.
The kit contains:

  • Applicator
  • Placebogel
  • QR code links for access to Blissel® Summary of Product Characteristics and Patient Information Leaflets.
Click here to order

Upcoming Webinars 2026

Our next FREE ONLINE
Webinar is on the 22nd Sept 2026
between 7.30pm – 9.30pm

Click here to find out more

My Blissel® Time to talk
Video Library

In depth discussions around various issues arising when treating the menopause with Dr Julie Oliver, Dr Michelle Olver, Dr Radhika Vohra, Dr Anne Connolly, Dr Diana Mansour and Nurse Consultant Nikki Noble.

Click here to open and play the videos

Ultra low dose estriol vaginal gel7,8

1. Nappi RE, Palacios S. Climacteric. 2014;17:3-9, 2. Moral E, et al. Menopause. 2018;25(12):1418-23. 3. Palma F, et al. Maturitas. 2018;108:18-23. 4. Krychman M, et al. J Sex Med 2017:14:425-433. 5. NAMS position statement. Menopause. 2020;27(9):976-92. 6. NICE. Menopause: diagnosis and management (NG23). Available from: https://www.nice.org.uk/guidance/ng23/chapter/recommendations. Accessed July 2026. 7. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics. 8. Cano A, et al. Menopause. 2012;19(10):1130-9.

Date of preparation: August 2026 | UK-BLS-692

BlisselⓇ (Estriol 50 Microgams/G Vaginal Gel)
Safety Information:

CLOSE X

  • For the treatment of postmenopausal vaginal atrophy symptoms, local estrogen therapy should only be initiated for symptoms that adversely affect quality of life.
  • BlisselⓇ 50 micrograms/g vaginal gel must not be combined with estrogen preparations for systemic treatment, as there are no studies of safety and risks with estrogen concentrations attained in combination treatment.
  • Intravaginal applicator may cause minor local trauma, especially in women with serious vaginal atrophy.
  • Before estriol treatment is initiated or reinstituted, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use.

Please refer to the Summary of Product Characteristics before prescribing.1

1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.

Common (≥1/100 to <1/10) and (≥1/1000 to <1/100) undesirable effects1

Date of preparation: August 2026 Item code: UK-BLS-671(2)